Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.

James F HowardVera BrilTed M BurnsRenato MantegazzaMalgorzata BilinskaAndrzej SzczudlikSaid BeydounFrancisco Javier Rodriguez De Rivera GarridoFredrik PiehlMariarosa RottoliPhilip Van DammeTuan VuAmelia EvoliMiriam FreimerTahseen MozaffarE Sally WardTorsten DreierPeter UlrichtsKatrien VerschuerenAntonio GugliettaHans de HaardNicolas LeupinJan J G M Verschuurennull null

Published in: Neurology (2019)

This study provides Class I evidence that efgartigimod is safe and well-tolerated in patients with gMG.

Keyphrases

myasthenia gravis
open label
double blind
placebo controlled
phase iii
randomized controlled trial